Stockscreener 앱 받기
23.83
2.32%
0.54
시장 영업 전:
23.83
전일 마감가:
$23.29
열려 있는:
$23.33
하루 거래량:
754.17K
Relative Volume:
0.96
시가총액:
$1.16B
수익:
$109.79M
순이익/손실:
$-153.49M
주가수익비율:
-7.4241
EPS:
-3.2098
순현금흐름:
$-172.59M
1주 성능:
-1.20%
1개월 성능:
+26.62%
6개월 성능:
+23.41%
1년 성능:
+117.63%
1일 변동 폭
$22.99
$23.89
1주일 범위
$22.68
$24.42
52주 변동 폭
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
23.83 | 1.16B | 109.79M | -153.49M | -172.59M | -3.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Jefferies | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline - MSN
UroGen earnings in focus: Can ZUSDURI drive commercial momentum? - Investing.com
Understanding Momentum Shifts in (URGN) - Stock Traders Daily
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
UroGen Pharma : 2025 Annual Report - marketscreener.com
UroGen Pharma (NASDAQ: URGN) seeks approvals on board, equity plan and bylaws - Stock Titan
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 - ChartMill
BlackRock (URGN) discloses 2.52M shares, 5.2% stake reported - Stock Titan
HC Wainwright Predicts Urogen Pharma Q1 Earnings - MarketBeat
Urogen Pharma Ltd at TD Cowen Healthcare Conference Transcript - GuruFocus
Urogen Pharma (NASDAQ:URGN) Rating Increased to Strong-Buy at Jefferies Financial Group - MarketBeat
HC Wainwright Predicts Urogen Pharma Q3 Earnings - MarketBeat
Avoiding Lag: Real-Time Signals in (URGN) Movement - Stock Traders Daily
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
UroGen Pharma (URGN) Stock: Trending Up? (Gains) 2026-04-22Certified Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
UroGen Pharma Ltd. (URGN) - Minichart
Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
UroGen Pharma Ltd stock (IL0011408896): Is its urology focus strong enough to unlock new upside? - AD HOC NEWS
UroGen Pharma (URGN) Stock: Momentum Analysis (Momentum Building) 2026-04-18Diversification - Xã Thanh Hà
UroGen Pharma Ltd. (NASDAQ: URGN) seeks 1,000,000-share plan increase - Stock Titan
UroGen Pharma Ltd | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Market Pulse: Is now the right time to enter UroGen Pharma LtdPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Discipline and Rules-Based Execution in URGN Response - Stock Traders Daily
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substant - GuruFocus
UroGen Pharma (URGN) Is Up 14.6% After Phase 3 ENVISION Data And LG-UTUC Outreach Push - Sahm
URGN SEC FilingsUrogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Urogen Pharma (NASDAQ:URGN) Shares Gap UpTime to Buy? - MarketBeat
Jefferies Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
Can UroGen Pharma (URGN) Stock Recover Now | URGN Q4 Earnings: Misses Estimates by $0.03Real Time Stock Idea Network - Xã Thanh Hà
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Sahm
UroGen Pharma Ltd. Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment Of Patients with Low-Grade Upper Tract Urothelial Cancer - marketscreener.com
UroGen Launches LG-UTUC Luminaries Initiative Recognizing - GlobeNewswire
Trend Report: Will UroGen Pharma Ltd stock benefit from M AEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Bull Bear: What are the risks of holding UroGen Pharma LtdWeekly Profit Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
Trend Recap: Is UroGen Pharma Ltd a cyclical or defensive stock2026 Reactions & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady - Yahoo Finance
URGN Stock Analysis: UroGen Pharma Ltd. Ordinary Shares dips 0.63% to hold $18.82 price level - Cổng thông tin điện tử tỉnh Lào Cai
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma Ltd.Ordinary Shares (NQ: URGN - The Chronicle-Journal
UroGen Pharma Ltd (UR8.DU) Income Statement - ca.finance.yahoo.com
Behavioral Patterns of URGN and Institutional Flows - Stock Traders Daily
Activity Recap: Will UroGen Pharma Ltd stock benefit from M AMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN - MarketBeat
UroGen’s Zusduri shows 72% event-free rate at 24 months By Investing.com - Investing.com South Africa
UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - GuruFocus
UroGen’s Zusduri shows 72% event-free rate at 24 months - Investing.com
Urogen Pharma Ltd. Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - marketscreener.com
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - GlobeNewswire
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):